Built Jobsite BBQ Raising Funds for Fragile X Research

Built employee Jason and his team hosted a BBQ fundraiser for FRAXA after his sons, Jaxson and Alex, were diagnosed with Fragile X.

Read More »

Repurposing FDA-Approved Drugs to Treat Major Depressive Disorder in Fragile X Syndrome

Depression is common in Fragile X, but current antidepressants need FMRP to work. Researchers will screen FDA-approved drugs to find effective options for FXS.

Read More »

FMR1 Renamed to Fragile X Messenger Ribonucleoprotein 1

The efforts of the European Fragile X Network (EFXN) have led to the renaming of the FMR1 gene to “Fragile X Messenger Ribonucleoprotein 1” gene and the Fragile X protein, FMRP, to "Fragile X Messenger Ribonucleoprotein." Families around the globe are celebrating the news as a significant step forward for acceptance and the removal of a term that evokes many negative feelings.

Read More »

VLM Commodities Charity Week Raises $10,000 for Fragile X Research

“Living with Fragile X is what we do—we keep going forward,” Lou shared. “FRAXA gives purpose, and I’m proud to support Charity Week.”

Read More »

How FRAXA Prioritizes Research, Explained

Dr. Mike Tranfaglia explains how FRAXA prioritizes research and the importance of looking at research from multiple angles. "It’s not either-or. It’s not we have a definitive treatment or we have a new drug treatment or we have a repurposing treatment. We can have all of those things, mixed or matched, in a personalized medicine kind of way and I think that’s what we’re headed for."

Read More »

Cape Coral Touch-A-Truck, Free, Family-Friendly Event

Join EHL Fragile X Foundation’s free Touch-A-Truck in Cape Coral! Explore fire trucks, police bikes, ambulances, swamp buggies, and more.

Read More »

Wine and Friends Are a Great Blend for Fragile X Research

Debra and Kevin hosted their first annual event for FRAXA in honor of their grandson Jackson, who has Fragile X syndrome.

Read More »

What FRAXA Is Excited about in the Upcoming Fragile X Research Grants, Explained

Dr. Mike Tranfaglia shares what FRAXA is excited about as we work through reviewing all of the submitted Fragile X research grant applications. We find it especially exciting that so many new clinical trials are starting right now, as our major emphasis is getting the drugs and other treatment strategies that we have tested in the Fragile X mouse model to patients in clinical trials.

Read More »

Gordon Research Conference for Fragile X and Autism-Related Disorders, Explained

The Fragile X and Autism-Related Disorders Gordon Research Conference is a biannual event that provides an international forum for the presentation and discussion of frontier research in these conditions. Dr. Mike Tranfaglia explains why this is the premier conference for researchers and the scientific community.

Read More »

Making Mittens for Fragile X

Carol spends over 2 hours crafting each fleece-lined mitten. Her handmade creations warm hands and support Fragile X research.

Read More »

Meet Archie!

Meet #FriendofFRAXA Archie! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
Banerjee team at College of Staten Island

Correcting Fragile X Syndrome Deficits by Targeting Neonatal PKCε Signaling in the Brain

Enhancing PKCε in early development normalized oxytocin, AMPAR signaling, and adult behavior in Fragile X mice, highlighting PKCε as a promising therapeutic target.

Read More »

Climbing 3 Mountains for Fragile X Research

Michael Leonard climbed three mountains in 24 hours to honor his son, Cole, who lives with Fragile X syndrome. A father’s love knows no limits.

Read More »

Potential Upcoming Advances in Fragile X Research

Dr. Peter Kind, Director of the Patrick Wild Centre and Professor of Developmental Neuroscience at the University of Edinburgh, and Dr. Nahum Sonenberg, James McGill professor of biochemistry at McGill University, share their optimism about the next 10 years of Fragile X research. They discuss where they think the next big discoveries will emerge.

Read More »
LEPAGE_jean-francois_CORBIN_francois

Lovamix: Clinical Trial of Combined Treatment of Minocycline and Lovastatin in Fragile X Syndrome

FRAXA funded the LovaMiX trial of lovastatin + minocycline for Fragile X. 2022 results show safety and support continued study of this dual-target treatment approach.

Read More »

FRAXA’s Most Successful End-Of-Year Campaign Ever!

Together, we made history! FRAXA’s 2021 campaign was our most successful ever, fueling hope for treatments and a cure for Fragile X.

Read More »

Neurodevelopmental Drug Development Summit Presentation

FRAXA president and co-founder, Katie Clapp was one of three patient advocacy leaders invited to kick off the Neurodevelopmental Drug Development Summit with a presentation on Fragile X, and FRAXA Scientific Advisor, Dr. Elizabeth Berry-Kravis also presented lessons learned from clinical trials in Fragile X Syndrome.

Read More »

Meet Jonathan!

Meet #FriendofFRAXA Jonathan! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

10 Year Vision for Collaborations That Transform Fragile X and Autism Research

The future offers hope for people living with Fragile X syndrome. Collaborations between the Fragile X community and other disability organizations help to provide understanding and advancement of research to bring effective treatments to families. FRAXA’s Dr. Mike Tranfaglia talks with Autism Science Foundation’s Allison Singer about the importance of their collaboration as we look forward to the next 10 years.

Read More »
Frank Kooy lab

GABA-A Receptor in Fragile X Syndrome

Published results from Dr. Frank Kooy reveal how GABAA receptor changes may hold the key to treating Fragile X syndrome.

Read More »

Characterization of a Novel CYFIP1 – Derived Peptidomimetic Restoring the Dysregulated mRNAs Translation: Toward An Innovative Therapeutic Strategy for FXS

This team is designing tiny “peptidomimetic” drugs that mimic FMRP’s function to rebalance protein production in the brain, aiming to treat Fragile X at its source.

Read More »

Bruins 50/50 Benefits Fragile X Research

FRAXA volunteers sold 50/50 raffle tickets at the Bruins game, raising $28,040 with the Bruins Foundation, half to FRAXA, half to one lucky fan!

Read More »

FX-Learn Clinical Trial for Children with Fragile X

Thirteen centers across the US enrolled children with Fragile X in a large-scale clinical trial of Novartis AFQ056. Dr. Elizabeth Berry-Kravis and colleagues aim to show that this targeted treatment — an mGluR5 blocker for Fragile X which failed in previous adult human trials — can be better evaluated by studying effects on learning in young children.

Read More »

Cannabinoids as a Treatment for Fragile X Syndrome

This team uses EEG to study sensory hypersensitivity in Fragile X. By testing drugs in mice, they aim to find treatments that calm brain overactivity.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)